Go Deep
Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,878 | -1.0 | 0.63 | 0.02 | 228.26 |
| Oct 2026 | 19,897 | -1.0 | 0.63 | 0.02 | 227.32 |
| Oct 2026 | 19,934 | -1.0 | 0.62 | 0.02 | 225.66 |
| Oct 2026 | 20,026 | -0.9 | 0.61 | 0.02 | 220.92 |
| Oct 2026 | 20,008 | -1.0 | 0.61 | 0.02 | 221.32 |
| Oct 2026 | 20,045 | -0.9 | 0.61 | 0.02 | 218.99 |
Kiora Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -2,079,010.0 | -2,417,984.0 | -6,516,521.0 | 26,806.0 |
| EPS | -0.3 | -0.6 | — | 0.0 |
Kiora Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 16,000,000.0 | 0.0 | 0.0 | — |
| Net Profit | -10,835,154.0 | 3,594,733.0 | -12,513,896.0 | -13,583,610.0 | — |
| EPS | -2.6 | 0.9 | -24.2 | -166.9 | — |
Kiora Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 24,253,300.0 | 36,484,484.0 | 13,711,870.0 | 18,678,259.0 | — |
| Total Liabilities | 8,126,764.0 | 10,724,708.0 | 7,602,216.0 | 7,270,659.0 | — |
| Total Equity | 16,126,536.0 | 25,759,776.0 | 6,109,654.0 | 11,407,600.0 | — |
Owes vs Owns
Kiora Pharmaceuticals, Inc. owed $0.29 for every $1 it owned in Jun 2026, down from $0.39 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.29× | 0.34× | 0.29× | 0.55× | 0.39× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Kiora Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 70.5%Receivables 13.7%Fixed assets (tangible) 1.6%Intangible assets 8.5%Other assets 5.8%
How it's funded — Dec 2025
Short-term debt 0.7%Long-term debt 0.8%Payables 4.4%Other liabilities 27.6%Shareholders' equity 66.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 17.1 | 26.8 | 2.5 | 6.0 |
| Receivables | 3.3 | 0.9 | 2.0 | 1.4 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.4 | 0.1 | 0.1 | 0.2 |
| Intangible assets | 2.1 | 6.7 | 8.8 | 10.7 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 1.4 | 2.1 | 0.3 | 0.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.2 | 0.0 | 0.0 | 0.1 |
| Long-term debt | 0.2 | 0.0 | 0.1 | 0.0 |
| Payables | 1.1 | 0.4 | 0.2 | 1.0 |
| Other liabilities | 6.7 | 10.3 | 7.3 | 6.2 |
| Shareholders' equity | 16.1 | 25.8 | 6.1 | 11.4 |
| Net tangible assets | 14.1 | 19.1 | -2.7 | 0.7 |
Kiora Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -9,961,176.0 | 8,559,115.0 | -9,556,951.0 | -10,428,133.0 | — |
| Investing Activities | 14,426,645.0 | -22,662,611.0 | 0.0 | 6,375.0 | — |
| Financing Activities | 265,655.0 | 15,498,155.0 | 5,966,066.0 | 8,620,921.0 | — |